-
1.发明申请USE OF RAPAMYCIN DERIVATIVES IN VASCULOPATHIES AND XENOTRANSPLANTATION 审中-公开RAPAMYCIN衍生物在血管造影和XENOTRANSPLANTATION中的应用公开(公告)号：US20140187574A1
公开(公告)日：2014-07-03
申请号：US14197368
申请日：2014-03-05
IPC分类号： A61K31/436
CPC分类号： A61K31/436
摘要： Use of a rapamycin derivative of formula I as defined in the claims for preventing or treating vasculopathies and manifestations of xenotransplantation.
摘要翻译： 在权利要求中定义的式I的雷帕霉素衍生物用于预防或治疗血管病变和异种移植的表现的用途。
-
2.发明授权Combinations of immunosuppressive agents for the treatment or prevention of graft rejections 有权用于治疗或预防移植排斥反应的免疫抑制剂的组合公开(公告)号：US08435520B2
公开(公告)日：2013-05-07
申请号：US13025347
申请日：2011-02-11
申请人： Hendrik J. Schuurman , Emanuele Luigi Maria Cozzi , Francoise Richard , Guy Taccard , David James Graham White , Peter John Friend , John Wallwork , Paolo Brenner
发明人： Hendrik J. Schuurman , Emanuele Luigi Maria Cozzi , Francoise Richard , Guy Taccard , David James Graham White , Peter John Friend , John Wallwork , Paolo Brenner
IPC分类号： A61K39/395 , A61K38/13 , A61K47/26 , A61K47/00
CPC分类号： A61K38/13 , A61K31/00 , A61K31/365 , A61K31/4745 , A61K2300/00
摘要： A pharmaceutical composition useful in the treatment or prevention of transgenic xenograft rejection comprising immunosuppressant compounds selected from the group consisting of an IL-2 transcription inhibitor and immunosuppressant compounds that immunosuppress for B-cell-mediated or antibody-mediated rejection of xenografts, and pharmaceutically acceptable diluents or carriers, and a method of preventing hyperacute rejection, reducing early graft damage, improving early xenograft function and promoting long term survival of said transgenic xenografts comprising the steps of i) contacting the body fluid removed from a human recipient with a xenoantigenic material which is bound to a biocompatible solid support, ii) reintroducing the treated body fluid into the recipient, and iii) treating the recipient with said pharmaceutical composition.
摘要翻译： 一种可用于治疗或预防转基因异种移植排斥的药物组合物，其包含免疫抑制剂化合物，其选自由免疫抑制异种移植物B细胞介导或抗体介导的排斥反应的IL-2转录抑制剂和免疫抑制剂化合物，以及药学上可接受的 稀释剂或载体，以及预防超急性排斥反应，减少早期移植物损伤，改善早期异种移植物功能并促进所述转基因异种移植物的长期存活的方法，包括以下步骤：i）将从人接受者移除的体液与异种抗生素材料接触， 与生物相容的固体支持物结合，ii）将经处理的体液重新引入受体中，和iii）用所述药物组合物治疗接受者。
-
3.发明申请COMBINATIONS OF IMMUNOSUPPRESSIVE AGENTS FOR THE TREATMENT OR PREVENTION OF GRAFT REJECTIONS 有权用于治疗或预防遗传因素的免疫抑制剂的组合公开(公告)号：US20110142953A1
公开(公告)日：2011-06-16
申请号：US13025347
申请日：2011-02-11
申请人： Hendrik J. SCHUURMAN , Emanuele Luigi COZZI , Francoise RICHARD , Guy TACCARD , David James Graham WHITE , Peter John FRIEND , John WALLWORK , Paolo BRENNER
发明人： Hendrik J. SCHUURMAN , Emanuele Luigi COZZI , Francoise RICHARD , Guy TACCARD , David James Graham WHITE , Peter John FRIEND , John WALLWORK , Paolo BRENNER
CPC分类号： A61K38/13 , A61K31/00 , A61K31/365 , A61K31/4745 , A61K2300/00
摘要： A pharmaceutical composition useful in the treatment or prevention of transgenic xenograft rejection comprising immunosuppressant compounds selected from the group consisting of an IL-2 transcription inhibitor and immunosuppressant compounds that immunosuppress for B-cell-mediated or antibody-mediated rejection of xenografts, and pharmaceutically acceptable diluents or carriers, and a method of preventing hyperacute rejection, reducing early graft damage, improving early xenograft function and promoting long term survival of said transgenic xenografts comprising the steps of i) contacting the body fluid removed from a human recipient with a xenoantigenic material which is bound to a biocompatible solid support, ii) reintroducing the treated body fluid into the recipient, and iii) treating the recipient with said pharmaceutical composition.
摘要翻译： 一种可用于治疗或预防转基因异种移植排斥的药物组合物，其包含免疫抑制剂化合物，其选自由免疫抑制异种移植物B细胞介导或抗体介导的排斥反应的IL-2转录抑制剂和免疫抑制剂化合物，以及药学上可接受的 稀释剂或载体，以及预防超急性排斥反应，减少早期移植物损伤，改善早期异种移植物功能并促进所述转基因异种移植物的长期存活的方法，包括以下步骤：i）将从人接受者移除的体液与异种抗生素材料接触， 与生物相容的固体支持物结合，ii）将经处理的体液重新引入受体中，和iii）用所述药物组合物治疗接受者。
-
4.发明授权Use of 40-O-(2-hydroxy)ethylrapamycin for treatment of restenosis and other disorders 有权40-O-（2-羟基）乙基雷帕霉素用于治疗再狭窄和其他疾病公开(公告)号：US06384046B1
公开(公告)日：2002-05-07
申请号：US09712359
申请日：2000-11-14
IPC分类号： A61K3144
CPC分类号： A61K31/436
摘要： This invention relates to the use of 40-O-(2-hydroxy)ethyl-rapamycin for the prevention or treatment of neointimal proliferation and thickening, restenosis, and vascular occlusion following vascular injury.
摘要翻译： 本发明涉及40-O-（2-羟基）乙基 - 雷帕霉素在血管损伤后预防或治疗新生内膜增生和增厚，再狭窄和血管闭塞的用途。
-
5.发明申请USE OF RAPAMYCIN DERIVATIVES IN VASCULOPATHIES AND XENOTRANSPLANTATION 审中-公开RAPAMYCIN衍生物在血管造影和XENOTRANSPLANTATION中的应用公开(公告)号：US20120177690A1
公开(公告)日：2012-07-12
申请号：US13357199
申请日：2012-01-24
IPC分类号： A61K31/436 , A61P35/00 , A61P37/06
CPC分类号： A61K31/436
摘要： Use of a rapamycin derivative of formula I as defined in the claims for preventing or treating vasculopathies and manifestations of xenotransplantation.
摘要翻译： 在权利要求中定义的式I的雷帕霉素衍生物用于预防或治疗血管病变和异种移植的表现的用途。
-
公开(公告)号：US20100152105A1
公开(公告)日：2010-06-17
申请号：US12715007
申请日：2010-03-01
CPC分类号： A61K31/436
摘要： The present invention is directed to the use of a rapamycin derivative of formula I in combination with cyclosporin for preventing or treating manifestations of chronic rejection in a recipient of an organ or tissue transplant.
摘要翻译： 本发明涉及式I的雷帕霉素衍生物与环孢菌素的组合用于预防或治疗器官或组织移植受者的慢性排斥反应的表现。
-
7.发明申请Combinations of Immunosupressive Agents for the Treatment or Prevention of Graft Rejections 审中-公开用于治疗或预防移植物排斥的免疫抑制剂的组合公开(公告)号：US20080199478A1
公开(公告)日：2008-08-21
申请号：US12109210
申请日：2008-04-24
申请人： Hendrik J. SCHUURMAN , Emanuele Luigi Cozzi , Francoise Richard , Guy Taccard , David James Graham White , Peter John Friend , John Wallwork , Paolo Brenner
发明人： Hendrik J. SCHUURMAN , Emanuele Luigi Cozzi , Francoise Richard , Guy Taccard , David James Graham White , Peter John Friend , John Wallwork , Paolo Brenner
IPC分类号： A61K38/13 , A61K39/395 , A61P43/00
CPC分类号： A61K38/13 , A61K31/00 , A61K31/365 , A61K31/4745 , A61K2300/00
摘要： A pharmaceutical composition useful in the treatment or prevention of transgenic xenograft rejection comprising immunosuppressant compounds selected from the group consisting of an IL-2 transcription inhibitor and immunosuppressant compounds that immunosuppress for B-cell-mediated or antibody-mediated rejection of xenografts, and pharmaceutically acceptable diluents or carriers, and a method of preventing hyperacute rejection, reducing early graft damage, improving early xenograft function and promoting long term survival of said transgenic xenografts comprising the steps of i) contacting the body fluid removed from a human recipient with a xenoantigenic material which is bound to a biocompatible solid support, ii) reintroducing the treated body fluid into the recipient, and iii) treating the recipient with said pharmaceutical composition.
摘要翻译： 一种可用于治疗或预防转基因异种移植排斥的药物组合物，其包含免疫抑制剂化合物，其选自由免疫抑制异种移植物B细胞介导或抗体介导的排斥反应的IL-2转录抑制剂和免疫抑制剂化合物，以及药学上可接受的 稀释剂或载体，以及预防超急性排斥反应，减少早期移植物损伤，改善早期异种移植物功能并促进所述转基因异种移植物的长期存活的方法，包括以下步骤：i）将从人接受者移除的体液与异种抗生素材料接触， 与生物相容的固体支持物结合，ii）将经处理的体液重新引入受体中，和iii）用所述药物组合物治疗接受者。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.014 秒)
